G. Schellong

4.4k total citations
106 papers, 2.6k citations indexed

About

G. Schellong is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, G. Schellong has authored 106 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Public Health, Environmental and Occupational Health, 39 papers in Hematology and 36 papers in Pathology and Forensic Medicine. Recurrent topics in G. Schellong's work include Acute Lymphoblastic Leukemia research (41 papers), Lymphoma Diagnosis and Treatment (30 papers) and Acute Myeloid Leukemia Research (28 papers). G. Schellong is often cited by papers focused on Acute Lymphoblastic Leukemia research (41 papers), Lymphoma Diagnosis and Treatment (30 papers) and Acute Myeloid Leukemia Research (28 papers). G. Schellong collaborates with scholars based in Germany, Austria and United States. G. Schellong's co-authors include J. Ritter, Jürgen Brämswig, Ursula Creutzig, W Dörffel, Marianne Riepenhausen, Richard Pötter, Alfred Reiter, Hansjörg Riehm, M Zimmermann and G. Henze and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

G. Schellong

99 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Schellong Germany 25 1.2k 1.2k 825 617 595 106 2.6k
Minnie Abromowitch United States 33 1.8k 1.4× 838 0.7× 1.1k 1.4× 784 1.3× 584 1.0× 67 3.0k
Aspasia Stamatoullas France 34 701 0.6× 1.7k 1.5× 1.4k 1.7× 290 0.5× 1.3k 2.2× 126 3.6k
J T Sandlund United States 20 1.6k 1.3× 447 0.4× 1.1k 1.4× 872 1.4× 446 0.7× 31 2.4k
Vita J. Land United States 27 1.1k 0.9× 241 0.2× 803 1.0× 725 1.2× 515 0.9× 61 2.4k
Dominic Culligan United Kingdom 26 415 0.3× 929 0.8× 1.0k 1.3× 152 0.2× 767 1.3× 75 2.9k
Emmanuel Plouvier France 24 373 0.3× 298 0.3× 631 0.8× 377 0.6× 446 0.7× 63 2.0k
H Rubie France 28 278 0.2× 590 0.5× 397 0.5× 259 0.4× 649 1.1× 75 2.3k
S Pavlovsky Argentina 21 412 0.3× 569 0.5× 408 0.5× 117 0.2× 585 1.0× 81 1.4k
Claudine Schmitt France 25 515 0.4× 611 0.5× 411 0.5× 285 0.5× 479 0.8× 60 1.9k
F Deméocq France 22 424 0.3× 234 0.2× 564 0.7× 382 0.6× 312 0.5× 78 1.5k

Countries citing papers authored by G. Schellong

Since Specialization
Citations

This map shows the geographic impact of G. Schellong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Schellong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Schellong more than expected).

Fields of papers citing papers by G. Schellong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Schellong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Schellong. The network helps show where G. Schellong may publish in the future.

Co-authorship network of co-authors of G. Schellong

This figure shows the co-authorship network connecting the top 25 collaborators of G. Schellong. A scholar is included among the top collaborators of G. Schellong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Schellong. G. Schellong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dörffel, W, Marianne Riepenhausen, H Lüders, Jürgen Brämswig, & G. Schellong. (2015). Secondary Malignancies Following Treatment for Hodgkin’s Lymphoma in Childhood and Adolescence. Deutsches Ärzteblatt international. 112(18). 320–7, i. 23 indexed citations
2.
Calaminus, Gabriele, W Dörffel, Katja Baust, et al.. (2014). Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002. Supportive Care in Cancer. 22(6). 1519–1529. 29 indexed citations
3.
4.
Schellong, G., W Dörffel, Alexander Claviez, et al.. (2005). Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group. Journal of Clinical Oncology. 23(25). 6181–6189. 70 indexed citations
5.
Körholz, Dieter, Alexander Claviez, Dirk Hasenclever, et al.. (2004). The Concept of the GPOH-HD 2003 Therapy Study for Pediatric Hodgkin's Disease: Evolution in the Tradition of the DAL/GPOH Studies. Klinische Pädiatrie. 216(3). 150–156. 40 indexed citations
6.
Creutzig, Ursula, M Zimmermann, J. Ritter, et al.. (1999). Definition of a standard‐risk group in children with AML. British Journal of Haematology. 104(3). 630–639. 107 indexed citations
7.
Schellong, G.. (1998). Pediatric Hodgkin’s disease: Treatment in the late 1990s. Annals of Oncology. 9. s115–s119. 20 indexed citations
8.
Schellong, G., I Hörnig-Franz, Bettina Rath, et al.. (1994). Reduzierung der Strahlendosen auf 20-30 Gy im Rahmen einer kombinierten Chemo-/Radiotherapie beim Morbus Hodgkin im Kindesalter. Klinische Pädiatrie. 206(4). 253–262. 20 indexed citations
9.
Schellong, G., Jürgen Brämswig, & I Hörnig-Franz. (1992). Treatment of children with Hodgkin's disease – Results of the German Pediatric Oncology Group. Annals of Oncology. 3. S73–S76. 30 indexed citations
10.
Rossi, R., U. Helmchen, & G. Schellong. (1992). Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome — a report of two cases. European Journal of Pediatrics. 151(5). 384–387. 22 indexed citations
11.
Boos, Joachim, et al.. (1991). Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemotherapy and Pharmacology. 28(6). 455–460. 41 indexed citations
12.
Creutzig, U., J. Ritter, & G. Schellong. (1990). Acute myelogenous leukemia in childhood : implications of therapy studies for future risk-adapted treatment strategies. Springer eBooks. 1 indexed citations
13.
Ritter, J., Ursula Creutzig, Alfred Reiter, H. Riehm, & G. Schellong. (1990). Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany. Journal of Cancer Research and Clinical Oncology. 116(1). 100–103. 16 indexed citations
14.
Ritter, J., Josef Vormoor, Ursula Creutzig, & G. Schellong. (1989). Prognostic significance of auer rods in childhood acute myelogenous leukemia: Results of the studies AML‐BFM‐78 and −83. Medical and Pediatric Oncology. 17(3). 202–209. 12 indexed citations
15.
Nieschlag, Eberhard, et al.. (1989). The long-term effects of different doses of cyclophosphamide (CP) on testicular function in prepubertal and pubertal boys with acute lymphoblastic leukemia (ALL). European Journal of Endocrinology. 120(3_Suppl). S119–S120. 1 indexed citations
16.
17.
Creutzig, Ursula, J. Ritter, H. Riehm, M. Budde, & G. Schellong. (1987). The Childhood AML Studies BFM-78 and -83: Treatment Results and Risk Factor Analysis. Hämatologie und Bluttransfusion. 30. 71–75. 13 indexed citations
18.
Schellong, G., et al.. (1984). Abgestufte Chemotherapie und reduzierte Strahlentherapie beim Morbus Hodgkin im Kindesalter. Oncology Research and Treatment. 7(4). 217–219. 1 indexed citations
19.
Henze, G., et al.. (1983). Prognosis of acute lymphoblastic leukemia related to initial findings and treatment.. PubMed. 132D. 445–9. 2 indexed citations
20.
Schellong, G., et al.. (1979). [The prognostic value of measuring cell size in acute childhood leukemia (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 191(2). 127–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Minnie Abromowitch Breakdown of academic impact, for papers by Aspasia Stamatoullas Breakdown of academic impact, for papers by J T Sandlund Breakdown of academic impact, for papers by Vita J. Land Breakdown of academic impact, for papers by Dominic Culligan Breakdown of academic impact, for papers by Emmanuel Plouvier Breakdown of academic impact, for papers by H Rubie Breakdown of academic impact, for papers by S Pavlovsky Breakdown of academic impact, for papers by Claudine Schmitt Breakdown of academic impact, for papers by F Deméocq
Rankless by CCL
2026